How does the GLP-1 receptor : molecular mechanisms and implications for research

GLP-1: From the gut to the brain

Le GLP-1 GLP-1 receptor agonist (GLP-1R) is a 30-amino-acid incretin hormone secreted by L cells in the distal small intestine in response to nutrient ingestion. Its discovery in the 1980s opened a field of research that led to the current GLP-1R agonists.

Native GLP-1 has a half-life of only 2-3 minutes in circulation, it is rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4). This instability has motivated the development of degradation-resistant analogues.

Structure of the GLP-1R receptor

Classification and architecture

The GLP-1R belongs to the GPCR family B1 (G Protein-Coupled Receptors), also known as the secretin receptor family. This family also includes the glucagon, GIP, and GHRH receptors.

Molecular architecture:

• Extracellular domain (ECD) : large N-terminal domain that captures the C-terminal end of the peptide ligand (two-step binding model)
• 7 transmembrane domains (7TM) : alpha helices crossing the membrane, forming the activation pocket where the N-terminal end of the peptide binds
• Intracellular domain : coupling interfaces to G proteins and beta-arrestins

Two-step linking model

The binding of GLP-1 to its receptor follows a two-step mechanism:

• Step 1 The C-terminal alpha helix of GLP-1 binds to the ECD domain with high affinity, anchoring the peptide
• Step 2 : the free N-terminal end of GLP-1 plunges into the transmembrane pocket, activating the receptor (conformational change)

Signaling lanes

Canonical Gαs/cAMP/PKA pathway

The main signaling pathway of GLP-1R is via the protein Gas :

• Activation of adenylyl cyclase → increase in intracellular cAMP
• Activation of PKA (Protein Kinase A) and Epac2 (Exchange Protein Activated by cAMP)
• In pancreatic beta cells: closure of K-ATP channels → depolarization → Ca2+ influx → insulin exocytosis
• This mechanism is glucose-dependent The effect is only activated when blood sugar is high.

beta-arrestin pathway

The GLP-1R is also regulated by the beta-arrestines :

• Recruitment of beta-arrestin-1 after receptor phosphorylation by GRKs
• Internalization of the receptor into endosomes
• Prolonged endosomal signaling (the receptor continues to signal after internalization)
• This endosomal signaling could explain the prolonged effects of long-acting agonists

Biased signage

A key concept in modern GLP-1R pharmacology is the signaling bias :

• Different agonists can preferentially activate certain pathways (Gαs vs beta-arrestin vs Gαq)
• Semaglutide exhibits a bias towards the Gαs/cAMP pathway compared to native GLP-1.
• Exendin-4 recruits beta-arrestins more strongly
• This bias influences clinical efficacy, tolerability, and extrapancreatic effects.

Tissue distribution of GLP-1R

Evolution of GLP-1R agonists in research

Optimization strategies

Synthetic GLP-1R agonists have been optimized using various strategies:

From mono-agonism to tri-agonism

• Monoagonist GLP-1R : Semaglutide — exclusive activation of GLP-1R
• Dual GLP-1R/GIPR agonist Tirzepatide — synergistic activation of two incretin receptors
• GLP-1R/GIPR/GcgR triple agonist Retatrutide — addition of glucagon receptor activation for hepatic thermogenesis

Frontiers of GLP-1R Research

Central effects (CNS)

One of the most active areas concerns the effects central GLP-1R agonists:

• Modulation of reward circuits (nucleus accumbens, ventral tegmental area)
• Addiction research (reducing craving in animal models)
• Neuroprotection in Parkinson's and Alzheimer's models
• Anti-inflammatory effects in microglia

Cardioprotection

Cardiovascular trials (SUSTAIN-6, PIONEER-6, SELECT) have demonstrated cardiovascular benefits of GLP-1R agonists, motivating research on:

• Direct endothelial protection via eNOS
• Reduction of vascular inflammation (IL-6, CRP)
• Anti-atherosclerotic effects independent of weight loss

Implications for peptide research

Understanding GLP-1R is essential for:

• Interpret the differences in efficacy between Semaglutide, Tirzepatide and Retatrutide
• Understanding why the route of administration (SC vs oral) influences the action profile
• Anticipate extra-metabolic effects (CNS, cardiovascular, renal)
• Evaluate new agonists in development (orforglipron, small molecule GLP-1R)

To compare with other GLP-1 molecules, see our comparison Retatrutide vs Tirzepatide vs Semaglutide.